Tags

Type your tag names separated by a space and hit enter

Dengue vaccines: Are they safe for travelers?
Travel Med Infect Dis. 2016 Jul-Aug; 14(4):378-83.TM

Abstract

The four dengue viruses (DENV) circulate among nearly one-half of the world's population in tropical and semitropical countries imposing a huge morbidity burden on travelers. Sanofipasteur has developed a tetravalent live-attenuated vaccine, Dengvaxia, recently approved by the World Health Organization and licensed in four dengue-endemic countries. An additional two dengue vaccines, developed by the National Institute of Allergy and Infectious Diseases (NIAID), USA and Takeda, are entering phase III testing. Dengvaxia is composed of four yellow fever 17D-DENV chimeras, the NIAID vaccine contains three mutagenized DENV and one DENV2/4 chimera while the Takeda vaccine contains an attenuated DENV 2 and three DENV 2-DENV chimeras. Which of these vaccines might be useful in protecting travelers against dengue infections and disease? Dengvaxia requires three doses administered over the course of one year but in addition has safety signals suggesting that susceptible individuals should not be vaccinated. The NIAID vaccine is promising as a travel vaccine as a single dose fully protected susceptible adults against live dengue 2 virus challenge. The protective efficacy and safety of the Takeda vaccine remain to be demonstrated.

Authors+Show Affiliations

Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, USA. Electronic address: halsteads@erols.com.BioMathematics and Statistics Group, Center for Mathematics, Fundamental Applications and Operations Research, Lisbon University, USA. Electronic address: mafsantos@fc.ul.pt.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27343438

Citation

Halstead, Scott B., and Maira Aguiar. "Dengue Vaccines: Are They Safe for Travelers?" Travel Medicine and Infectious Disease, vol. 14, no. 4, 2016, pp. 378-83.
Halstead SB, Aguiar M. Dengue vaccines: Are they safe for travelers? Travel Med Infect Dis. 2016;14(4):378-83.
Halstead, S. B., & Aguiar, M. (2016). Dengue vaccines: Are they safe for travelers? Travel Medicine and Infectious Disease, 14(4), 378-83. https://doi.org/10.1016/j.tmaid.2016.06.005
Halstead SB, Aguiar M. Dengue Vaccines: Are They Safe for Travelers. Travel Med Infect Dis. 2016 Jul-Aug;14(4):378-83. PubMed PMID: 27343438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dengue vaccines: Are they safe for travelers? AU - Halstead,Scott B, AU - Aguiar,Maira, Y1 - 2016/06/22/ PY - 2016/06/05/received PY - 2016/06/16/revised PY - 2016/06/17/accepted PY - 2016/6/26/entrez PY - 2016/6/28/pubmed PY - 2017/4/22/medline KW - Antibody dependent enhancement KW - Arbovirus KW - Dengue KW - Efficacy KW - Vaccine SP - 378 EP - 83 JF - Travel medicine and infectious disease JO - Travel Med Infect Dis VL - 14 IS - 4 N2 - The four dengue viruses (DENV) circulate among nearly one-half of the world's population in tropical and semitropical countries imposing a huge morbidity burden on travelers. Sanofipasteur has developed a tetravalent live-attenuated vaccine, Dengvaxia, recently approved by the World Health Organization and licensed in four dengue-endemic countries. An additional two dengue vaccines, developed by the National Institute of Allergy and Infectious Diseases (NIAID), USA and Takeda, are entering phase III testing. Dengvaxia is composed of four yellow fever 17D-DENV chimeras, the NIAID vaccine contains three mutagenized DENV and one DENV2/4 chimera while the Takeda vaccine contains an attenuated DENV 2 and three DENV 2-DENV chimeras. Which of these vaccines might be useful in protecting travelers against dengue infections and disease? Dengvaxia requires three doses administered over the course of one year but in addition has safety signals suggesting that susceptible individuals should not be vaccinated. The NIAID vaccine is promising as a travel vaccine as a single dose fully protected susceptible adults against live dengue 2 virus challenge. The protective efficacy and safety of the Takeda vaccine remain to be demonstrated. SN - 1873-0442 UR - https://www.unboundmedicine.com/medline/citation/27343438/Dengue_vaccines:_Are_they_safe_for_travelers L2 - https://linkinghub.elsevier.com/retrieve/pii/S1477-8939(16)30071-0 DB - PRIME DP - Unbound Medicine ER -